COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry

• Published in: Kidney360 2022-02, Vol.3 (2), p.293-306
• Main Authors: Waldman, Meryl, Soler, Maria Jose, García-Carro, Clara, Lightstone, Liz, Turner-Stokes, Tabitha, Griffith, Megan, Torras, Joan, Martinez Valenzuela, Laura, Bestard, Oriol, Geddes, Colin, Flossmann, Oliver, Budge, Kelly L, Cantarelli, Chiara, Fiaccadori, Enrico, Delsante, Marco, Morales, Enrique, Gutierrez, Eduardo, Niño-Cruz, Jose A, Martinez-Rueda, Armando J, Comai, Giorgia, Bini, Claudia, La Manna, Gaetano, Slon, Maria F, Manrique, Joaquin, Avello, Alejandro, Fernandez-Prado, Raul, Ortiz, Alberto, Marinaki, Smaragdi, Martin Varas, Carmen Rita, Rabasco Ruiz, Cristina, Sierra-Carpio, Milagros, García-Agudo, Rebeca, Fernández Juárez, Gema, Hamilton, Alexander J, Bruchfeld, Annette, Chrysochou, Constantina, Howard, Lilian, Sinha, Smeeta, Leach, Tim, Agraz Pamplona, Irene, Maggiore, Umberto, Cravedi, Paolo
• Format: Article
• Language: English
• Subjects: Acute Kidney Injury - complications; COVID-19 - epidemiology; Follow-Up Studies; Humans; Medicin och hälsovetenskap; Original Investigation; Registries; SARS-CoV-2
• ISSN: 2641-7650; 2641-7650
• DOI: 10.34067/KID.0006612021

The acute and long-term effects of severe acute respiratory syndrome coronavirus 2 infection in individuals with GN are still unclear. To address this relevant issue, we created the International Registry of COVID-19 infection in GN. We collected serial information on kidney-related and -unrelated outcomes from 125 GN patients (63 hospitalized and 62 outpatients) and 83 non-GN hospitalized patients with coronavirus disease 2019 (COVID-19) and a median follow-up period of 6.4 (interquartile range 2.3-9.6) months after diagnosis. We used logistic regression for the analyses of clinical outcomes and linear mixed models for the longitudinal analyses of eGFR. All multiple regression models were adjusted for age, sex, ethnicity, and renin-angiotensin-aldosterone system inhibitor use. After adjustment for pre-COVID-19 eGFR and other confounders, mortality and AKI did not differ between GN patients and controls (adjusted odds ratio for AKI=1.28; 95% confidence interval [CI], 0.46 to 3.60; =0.64). The main predictor of AKI was pre-COVID-19 eGFR (adjusted odds ratio per 1 SD unit decrease in eGFR=3.04; 95% CI, 1.76 to 5.28;